Drug-resistant epilepsy: Dr. Patrick Kwan

Drug‑resistant epilepsy remains a major challenge for patients, families and health systems, affecting a sizable minority of people with seizures and prompting a shift from medication‑only strategies to broader treatment options.

Definition and Prevalence

The International League Against Epilepsy (ILAE) defines drug‑resistant epilepsy as a condition that has not responded to two appropriately chosen anti‑seizure medicines given at adequate doses, and durations. The definition, published in 2010, was designed to be simple and actionable for clinicians worldwide. Studies using this definition report that roughly 20 % to one‑third of people with epilepsy meet the criteria, indicating a substantial burden.

Why Some Patients Do Not Respond

Several factors increase the likelihood of resistance. Structural abnormalities such as hippocampal sclerosis or focal cortical dysplasia are frequently linked to poor drug response and often lead to surgical evaluation. Mental‑health comorbidities, notably depression and anxiety, are also associated with reduced seizure control.

Researchers propose multiple biological mechanisms: over‑expression of drug‑efflux transporters at the blood‑brain barrier, alterations in drug targets (glutamate, GABA receptors, ion channels), and the overall severity of the epileptic network. Inflammation, blood‑brain barrier breakdown, and perivascular (glymphatic) system dysfunction are additional areas of investigation, though their exact roles remain uncertain.

“Pseudo” Drug Resistance

Not all apparent treatment failures reflect true resistance. Misdiagnosis, use of an inappropriate medication for the specific seizure type, sub‑therapeutic dosing, or lifestyle triggers can all mimic drug resistance. Video‑EEG monitoring often clarifies the diagnosis; up to 30 % of patients referred for drug‑resistant epilepsy are re‑classified after such evaluation.

Clinical Path Forward

When two medicines have failed, clinicians should first verify that true resistance is present, then discuss non‑drug options—surgery, dietary therapy, or neuromodulation—early in the care pathway. Individualized plans, shaped by patient preferences and expectations, are essential. Multidisciplinary teamwork involving neurologists, surgeons, psychologists, nurses and allied health professionals improves the chances of achieving seizure freedom.

Did You Know? The ILAE’s original drug‑resistance definition, published in 2010, was deliberately simple to be usable in both high‑resource and resource‑poor settings, covering 60 % to 80 % of the global epilepsy population.

Expert Insight: While the 20‑30 % prevalence of drug‑resistant epilepsy may seem modest, even a modest 5 % improvement in seizure‑free rates could translate into billions of dollars saved in national productivity, underscoring the economic as well as personal stakes of advancing treatment.

Economic Impact

A German analysis estimates that each patient with drug‑resistant epilepsy incurs direct costs of €12,000–€14,000 per year. A simulation based on Australian data suggests that raising seizure‑free rates by just 5 % could save billions in gross domestic product, highlighting the broader societal benefits of better outcomes.

Future Directions

Ongoing ILAE work aims to refine the resistance definition, potentially incorporating individualized predictions from artificial‑intelligence models. Biomarker discovery—leveraging AI to uncover patterns beyond traditional statistics—may enable earlier identification of patients who would benefit from non‑drug interventions.

For a deeper look at the original definition, see the ILAE consensus proposal (2010). The economic analysis is available in this Neurology study.

Frequently Asked Questions

What is drug‑resistant epilepsy?

It is defined by the ILAE as epilepsy that has not responded to two appropriate anti‑seizure medications given at adequate doses and durations.

How common is drug‑resistant epilepsy?

Studies using the ILAE definition report that about 20 % to one‑third of people with epilepsy meet the criteria for drug resistance.

What should clinicians do after two medications fail?

First, confirm that true resistance exists by ruling out misdiagnosis, inappropriate drug choice, dosing errors or lifestyle factors—often through video‑EEG monitoring. Then discuss non‑drug treatments such as surgery, diet or neuromodulation, and involve a multidisciplinary team to tailor the plan to the patient’s needs.

How might emerging technologies like AI change the way we identify and treat drug‑resistant epilepsy?